

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BRADDOCK et al.

Serial No. 09/743,516

Filed: January 11, 2001

Title: PHARMACEUTICAL USES OF NAB1 AND NAB2

Atty Dkt. 1430-261

C#

M#

Group Art Unit: 1632

Examiner: S.D. Priebe

Date: April 18, 2002



RECEIVED

APR 19 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

AMENDMENT UNDER 37 CFR § 1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 18 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment 2 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)
 Please enter the previously unentered , filed
 Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
 Applicant claims "small entity" status. Statement filed herewith -\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: **Abstract of the Disclosure; Associate Power of Attorney; and a Request for Drawing Change along with copies of Figures 2a and 3a marked-up in red.** \$ 0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
 Arlington, Virginia 22201-4714
 Telephone: (703) 816-4000
 Facsimile: (703) 816-4100
 GRT:ap

NIXON & VANDERHYE P.C.
 By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 



THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9 B
4-22-02
P.2

RECEIVED

APR 19 2002

TECH CENTER 1600/2900

In re Patent Application of

BRADDOCK et al.

Appln. No. 09/743,516

Filed: January 31, 2001

Atty. Ref.: 1430-261

Group Art Unit: 1632

Examiner: S.D. Priebe

FOR: PHARMACEUTICAL USES OF NAB1 AND NAB2

* * *

AMENDMENT UNDER 37 CFR § 1.111

April 18, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the pending Office Action (Paper No. 6) of January 18, 2002 entry and consideration of the following amendments and remarks are respectfully requested.

IN THE CLAIMS

Kindly enter the following amended claim.

15. (Amended) A method of treatment of cell proliferation disorders associated with wound healing in a mammal, which method comprises administration to a wound site of the mammal a pharmaceutical composition comprising a nucleic acid molecule comprising a sequence encoding an NAB1 or NAB2 polypeptide, or a biologically active fragment thereof, together with one or more pharmaceutically acceptable carriers thereof.

Kindly cancel claims 1-14 and 16-22 without prejudice or disclaimer, and add the following new claims in lieu of the canceled elected claims.

23. (New) A method of treatment of cell proliferation disorders associated with wound healing in a mammal, which method comprises administration to a wound site of the